Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Sort descending Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Eylea Aflibercept Macular edema, branch retinal vein occlusion Reimburse with clinical criteria and/or conditions Complete
Eylea Aflibercept Macular degeneration, age-related List with criteria/condition Complete
Eylea Aflibercept Macular edema, diabetic List with clinical criteria and/or conditions Complete
Eylea Aflibercept Macular edema, central retinal vein occlusion List with clinical criteria and/or conditions Complete
Eylea HD aflibercept 8mg/0.07mL macular degeneration, age related Active
Eylea HD aflibercept 8mg/0.07mL diabetic macular edema Active
Replagal Agalsidase alfa Fabry Disease Do not list Complete
Fabrazyme Agalsidase beta Fabry Disease Do not list Complete
Fabrazyme Agalsidase beta Fabry Disease Do not list Complete
Proleukin Aldesleukin (IL-2) In-transit Melanoma Reimburse Complete